['age-related macular degeneration']
['squalamine lactate ophthalmic solution, 0.2%', 'placebo ophthalmic solution', 'ranibizumab']

        Inclusion Criteria:

          -  Age ≥ 50 years

          -  A diagnosis of choroid neovascularization (CNV) secondary to AMD with CNV comprising
             at least 50% of the total lesion area on fluorescein angiography (FA)

          -  Central subfield thickness (spectral domain (SD)-OCT central 1 mm) of ≥ 300 μm

          -  Best-corrected visual acuity (BCVA) 20/40 to 20/320 (73- to 24-letter score on the
             Early Treatment of Diabetic Retinopathy Study [ETDRS] chart)

        Exclusion Criteria:

          -  Neovascularization secondary to any other condition than AMD in the study eye; Blood
             occupying greater than 50% of the AMD lesion, or blood > 1.0 sq. mm underlying the
             fovea

          -  Pigment epithelial detachment (PED) without associated subretinal fluid and/or cystic
             retinal changes

          -  Clinical evidence of diabetic retinopathy or diabetic macular edema in the study eye

          -  Confounding ocular conditions in the study eye which will affect interpretation of
             OCT, VA or assessment of macular appearance (e.g., cataract, epiretinal membrane,
             retinal vascular occlusive disease)

          -  Fibrosis or atrophy, retinal epithelial tear in the center of the fovea in the study
             eye or any condition preventing VA improvement

          -  Uncontrolled glaucoma in the study eye, or currently receiving topical glaucoma
             medication in the study eye
      